Homoharringtonine/omacetaxine mepesuccinate: The long and winding road to food and drug administration approval

Hagop M. Kantarjian, Susan O'Brien, Jorge Cortes

Research output: Contribution to journalReview article

43 Scopus citations

Abstract

Homoharringtonine/omacetaxine is a unique agent with a long history of research development. It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors. Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review.

Original languageEnglish (US)
Pages (from-to)530-533
Number of pages4
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number5
DOIs
StatePublished - Oct 2013

Keywords

  • CML
  • Homoharringtonine (HHT)
  • Omacetaxine mepesuccinate
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Homoharringtonine/omacetaxine mepesuccinate: The long and winding road to food and drug administration approval'. Together they form a unique fingerprint.

  • Cite this